Details of the Drug

General Information of Drug (ID: DM5YF4M)

• Drug Name: Droxidopa
• Synonyms: droxidopa; 23651-95-8; L-DOPS; Northera; (2S,3R)-2-amino-3-(3,4-dihydroxyphenyl)-3-hydroxypropanoic acid; threo-Dopaserine; 3916-18-5; DOPS; DL-threo-DOPS; L-Threodops; DL-threo-3,4-Dihydroxyphenylserine; DL-threo-Droxidopa; DL-threo-Dihydroxyphenylserine; UNII-J7A92W69L7; SM 5688; CHEBI:31524; Droxidopa (L-DOPS); threo-beta,3-Dihydroxy-DL-tyrosine; EINECS 223-480-5; beta,3-Dihydroxy-DL-tyrosine threo-; BRN 2852792; L-threo-dihydroxyphenylserine; DL-threo-3-(3,4-Dihydroxyphenyl)serine; Serine, 3-(3,4-dihydroxyphenyl)-, DL-threo-

Indication

Disease Entry	ICD 11	Status	REF
Chronic fatigue syndrome	8E49	Approved	[1]
Neurogenic orthostatic hypotension	8D87.0Y	Approved	[2]
Pure autonomic failure	N.A.	Approved	[1]

• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 1:
  Molecular Weight (mw); 213.19
  Logarithm of the Partition Coefficient (xlogp); -3.2
  Rotatable Bond Count (rotbonds); 3
  Hydrogen Bond Donor Count (hbonddonor); 5
  Hydrogen Bond Acceptor Count (hbondacc); 6
• ADMET Property:
  Bioavailability: The bioavailability of drug is 90% []
  Half-life: The concentration or amount of drug in body reduced by one-half in 2 - 3 hours [3]
  Metabolism: The drug is metabolized via the aromatic L-amino acid decarboxylase []
• Chemical Identifiers:
  Formula: C9H11NO5
  IUPAC Name: (2S,3R)-2-amino-3-(3,4-dihydroxyphenyl)-3-hydroxypropanoic acid
  Canonical SMILES: C1=CC(=C(C=C1[C@H]([C@@H](C(=O)O)N)O)O)O
  InChI: InChI=1S/C9H11NO5/c10-7(9(14)15)8(13)4-1-2-5(11)6(12)3-4/h1-3,7-8,11-13H,10H2,(H,14,15)/t7-,8+/m0/s1
  InChIKey: QXWYKJLNLSIPIN-JGVFFNPUSA-N
• Cross-matching ID:
  PubChem CID: 92974
  ChEBI ID: CHEBI:31524
  CAS Number: 23651-95-8
  DrugBank ID: DB06262
  TTD ID: D0I3RO
  INTEDE ID: DR0552
  ACDINA ID: D00219
• Repurposed Drugs (RPD): Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
DOPA decarboxylase (DDC) Main DME	DETK9CN	DDC_HUMAN	Substrate	[4]

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Droxidopa (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Methylene blue	DMJAPE7	Moderate	Additive hypertensive effects by the combination of Droxidopa and Methylene blue.	Acquired methaemoglobinaemia [3A93]	[5]
Levalbuterol	DM5YBO1	Moderate	Additive hypertensive effects by the combination of Droxidopa and Levalbuterol.	Asthma [CA23]	[5]
Vilanterol	DMF5EK1	Moderate	Additive hypertensive effects by the combination of Droxidopa and Vilanterol.	Chronic obstructive pulmonary disease [CA22]	[5]
LEVONORDEFRIN	DMWDJ0H	Moderate	Additive hypertensive effects by the combination of Droxidopa and LEVONORDEFRIN.	Discovery agent [N.A.]	[5]
Ozanimod	DMT6AM2	Moderate	Additive hypertensive effects by the combination of Droxidopa and Ozanimod.	Multiple sclerosis [8A40]	[6]

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Allura red AC dye	E00338	33258	Colorant
FD&C blue no. 1	E00263	19700	Colorant
FD&C blue no. 2	E00446	2723854	Colorant
Hydrazine yellow	E00409	164825	Colorant
Mannitol	E00103	6251	Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Eisenoxyd	E00585	56841934	Colorant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Ferrosoferric oxide	E00231	14789	Colorant
Magnesium stearate	E00208	11177	lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Droxidopa 300 mg capsule	300 mg	Oral Capsule	Oral
Droxidopa 100 mg capsule	100 mg	Oral Capsule	Oral
Droxidopa 200 mg capsule	200 mg	Oral Capsule	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

• [1] Droxidopa FDA Label
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7391).
• [3] Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
• [4] L-Dihydroxyphenylserine (L-DOPS): a norepinephrine prodrug. Cardiovasc Drug Rev. 2006 Fall-Winter;24(3-4):189-203.
• [5] Product Information. Northera (droxidopa). Chelsea Therapeutics Inc, Charlotte, NC.
• [6] Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]